http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0627928-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_356c119b30c248dccde5bf56a92c1d8a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-02 |
| filingDate | 1993-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03f7623709ea5c35e637f08e8faf41eb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a82af3145aa0ed0f25a31ebafe2c2bc |
| publicationDate | 1994-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0627928-A1 |
| titleOfInvention | Use of muramyl peptide for the treatment of toxicity |
| abstract | Muramyl peptide compounds are effective in the treatment of toxicity, particularly when this condition arises from the abuse of alcohol, hypnotics or sedatives, anesthetics, opioids or drugs in general. Said muramyl peptide compound can be represented either by the general formula (I) or by the formula (II). Preferred compounds include the following: prototype MDP, muroctasin, MTP-PE, murabutide, t-MDP, N-acetyl-glucosaminyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine (GMDP) and N- acid acetyl-glucosaminyl-N-acetyl-muramyl-L-alanyl-D-glutamic (GMDP-A). |
| priorityDate | 1992-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 754.